MERCK & CO INC

Merck insider sales reveal quiet executive portfolio shifts—EVP Guindo Chirfi sells 10k shares amid routine Rule 144 trades, but fundamentals stay strong.

Merck insider buying signals confidence in MRK’s immuno‑oncology pipeline, showing a net‑long stance amid rising stock and upcoming product launches.

Merck insider Christine Seidman buys $2.7M in phantom‑stock, signaling confidence in its pipeline and growth despite a mixed market.

Merck insider buys phantom stock, boosting confidence as FDA approvals and oncology trials drive a hopeful growth narrative.

Insider buying of Merck phantom‑stock units signals executive confidence in its antiviral, immuno‑oncology pipeline and could hint at future upside for investors.

Merck insiders’ bulk phantom‑stock purchases signal strong confidence in its drug pipeline and growth prospects—an encouraging cue for investors seeking future upside.

Merck insider buying signals confidence in its oncology momentum, with executives buying shares as earnings rise—an indicator for investors to watch.

Merck insiders’ April 29 buy signals management confidence in oncology and vaccine growth, boosting investor sentiment amid upbeat social‑media buzz.

Merck insider trades reveal confidence in its digital‑first strategy, with EVP David Michael buying shares amid rising buzz and positive sentiment—potential upside for investors.

Merck insider buying shows confidence in its vaccine and oncology pipeline, suggesting solid mid‑term earnings growth amid mixed market sentiment.